clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Proteinuria D011507 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Endometriosis D004715 29 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Periodontitis D010518 22 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Whittemore KR and Cohen M Imaging and review of a large pre-auricular pilomatrixoma in a child. 2012 World J Radiol pmid:22761984
Grande M et al. Helicobacter pylori and gastroesophageal reflux disease. 2008 World J Surg Oncol pmid:18601740
Cavanna L et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. 2008 World J Surg Oncol pmid:18353178
Lai YC et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. 2003 World J. Gastroenterol. pmid:12854158
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Si JM et al. Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. 2005 World J. Gastroenterol. pmid:15948255
Hagiwara T et al. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. 2007 World J. Gastroenterol. pmid:17657838
Sanches BS et al. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. 2016 World J. Gastroenterol. pmid:27672279
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Robles-Jara C et al. Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? 2008 World J. Gastroenterol. pmid:18473407
Koussoulas V et al. Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. 2007 World J. Gastroenterol. pmid:17729416
Gumurdulu Y et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. 2004 World J. Gastroenterol. pmid:14991935
Ahmad N et al. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. 2009 World J. Gastroenterol. pmid:19575497
Guo CY et al. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. 2004 World J. Gastroenterol. pmid:14991953
Mirbagheri SA et al. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. 2006 World J. Gastroenterol. pmid:16937475
Luo XF et al. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. 2016 World J. Gastroenterol. pmid:27433095
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Ching SS et al. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. 2008 World J. Gastroenterol. pmid:18609709
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Iannone A et al. New fecal test for non-invasive detection: A diagnostic accuracy study. 2018 World J. Gastroenterol. pmid:30038469
Sun QJ et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. 2010 World J. Gastroenterol. pmid:20976850
Gisbert JP "Rescue" regimens after Helicobacter pylori treatment failure. 2008 World J. Gastroenterol. pmid:18803350
Chuah SK et al. A new look at anti-Helicobacter pylori therapy. 2011 World J. Gastroenterol. pmid:22046084
Deng ZH et al. Influence of Helicobacter pylori infection on ghrelin levels in children. 2012 World J. Gastroenterol. pmid:23049220
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Buzás GM and Józan J First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. 2006 World J. Gastroenterol. pmid:16981260
Babic Z et al. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. 2005 World J. Gastroenterol. pmid:15884110
Chen SJ et al. Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients. 2008 World J. Gastroenterol. pmid:18350632
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Abadi ATB Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. 2017 World J. Gastroenterol. pmid:29085187
Ji F et al. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. 2006 World J. Gastroenterol. pmid:16586550
Khan A et al. Antibiotic resistance and cagA gene correlation: a looming crisis of Helicobacter pylori. 2012 World J. Gastroenterol. pmid:22611319
Molina-Infante J and Gisbert JP Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:25132750
Zhou Q et al. Drug utilization of clarithromycin for gastrointestinal disease treatment. 2008 World J. Gastroenterol. pmid:18932287
Sereni G et al. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22969227
Isomoto H et al. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15786539
Wang HH et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. 2005 World J. Gastroenterol. pmid:15786549
Aydemir S et al. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15682477
O'Morain C Role of Helicobacter pylori in functional dyspepsia. 2006 World J. Gastroenterol. pmid:16718752
Wang CH et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. 2015 World J. Gastroenterol. pmid:26494972
Sun WH et al. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. 2005 World J. Gastroenterol. pmid:15832421
Bustamante-Rengifo JA et al. Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. 2017 World J. Gastroenterol. pmid:28373764
Zhao LJ et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. 2014 World J. Gastroenterol. pmid:24782630
Nishida T et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. 2014 World J. Gastroenterol. pmid:24764674
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Gao XZ et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. 2010 World J. Gastroenterol. pmid:20818821
Mabe K et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? 2009 World J. Gastroenterol. pmid:19750572
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Riquelme A et al. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. 2007 World J. Gastroenterol. pmid:17589948
Ersoy O et al. H pylori infection in patients with Behcet's disease. 2007 World J. Gastroenterol. pmid:17589951